

Special Issue

Brain Tumor Microenvironment and Host Role: Implications for Immunotherapy

Message from the Guest Editor

Glioblastoma (GBM) is a highly lethal brain tumor with a poor response to immunotherapies that have been successful in more immunogenic cancers with a less immunosuppressive tumor microenvironment (TME). In this Special Issue, we will focus on the molecular, histopathological and imaging features of the primary and metastatic brain tumor microenvironment. This Special Issue will include pre-clinical and clinical studies that focus on biological characterization, physiological insights, clinico-pathological applications including advanced imaging techniques and the identification of new potential therapeutic targets and agents. The studies included in this Special Issue may be based on preclinical models as well as clinical series. Original research manuscripts are favored. High-quality systematic reviews and meta-analyses will be also considered for publication. We look forward to receiving your contributions.

Guest Editor

Dr. Susobhan Sarkar

1. Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada
2. Cumming School of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, AB T2N 4N1, Canada

Deadline for manuscript submissions

25 May 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/217022

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).